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Protein kinases are clinically relevant, attractive
drug targets for cancer. One major problemwith
kinase inhibitors is broad promiscuity, causing
off-target actions and side effects. In silico
prediction of targets of a compound would
immensely facilitate and accelerate drug devel-
opment. Using a virtual ‘‘inverse’’ screening ap-
proach, where single compounds are docked
into protein structures froma database, we iden-
tify among known targets of indirubin derivatives
phosphoinositide-dependent kinase 1 (PDK1) as
a target of one derivative (6BIO) in particular.
This prediction is functionally supported by an
in vitro kinase assay, inhibition of intracellular
phosphorylation of PDK1-substrates, and inhibi-
tion of endothelial cell migration, which highly
depends on PDK1. Virtual inverse screening
combined with biological tests, thus, is pro-
posed as a valuable tool for the drug discovery
process and re-examination of already estab-
lished kinase inhibitors.
INTRODUCTION
During the last years, protein kinases have been recog-
nized as central drug targets for tumor therapy [1]; among
the successfully targeted ones are MAP kinases [2], re-
ceptor tyrosin kinases [3], and kinases of the PI3-kinase/
Akt/mTOR signaling pathway [4, 5]. This progress was
considerably boosted by the clinical success of small mo-
lecular inhibitors, like Gleevec (Novartis) or Iressa (Astra-
Zeneca). One problematic issue with kinase inhibitors is
specificity since they generally bind at the relatively con-
served ATP binding pocket of the kinase family [6, 7].
However, it has also recently been suggested that the bi-
ological activity of kinase inhibitorsmay rely on amultispe-
cific inhibition of different kinases [8]. In order to be able to
judge both positive and negative effects of multispecific-
ity, it is necessary to reliably identify the cellular targetsChemistry & Biology 14, 1207–121of inhibitors. Conventionally, kinase inhibitor activity and
specificity is tested in vitro within a defined panel of iso-
lated kinases [6]. This approach, however, has the limita-
tion that potential targets of the compound tested may
be overlooked, if they are not in the panel. In addition, me-
dium or high throughput testing of different compounds
against a comprehensive panel of kinases is resource in-
tensive, and the results still need to be confirmed in cellu-
lar assays and in vivo. Conventional structure based in sil-
ico approaches do not address specificity, as in general,
only one target is tested against different compounds of
interest. Thus, some other, more-relevant target structure
may be overlooked. ‘‘Inverse screening,’’ where a single
compound is docked into different protein structures
that are documented in protein databases, has been sug-
gested [9, 10] and was recently applied by us to the prob-
lem of artificial receptor design [11]. Such an approach
has the advantage that it can in principle be applied on
large numbers of compounds and, thus, be used already
at the discovery stage of drug-development projects.
However, to our knowledge, inverse screening has to
date neither been proven in practice nor has it been tested
for its accuracy within a large family of proteins. We here
use inverse screening to identify kinase targets for three
derivatives of indirubin (Figure 1G), namely 5-bromo-indir-
ubin-30oxime (5BIO), 6-bromo-indirubin-30oxime (6BIO),
and 7-bromo-indirubin-30oxime (7BIO). All three com-
pounds are derivatives of indirubin, a trace isomer of the
indigo dye. Indirubin has been identified as active principle
in a traditional Chinese medicine against chronic myelog-
enous leukemia (CML) with various biological effects on
a cellular basis [12]. Due to its poor solubility in water, in-
dirubin is no longer in clinical use [13], but a vast number of
derivatives have been generated as anticancer drugs and
scaffolds for kinase inhibitors [14, 15]. Although the three
compounds are structurally very similar, their biological
effects differ largely [16]: while 5BIO and 6BIO seem to
be inhibitors of CDKs, of GSK-3b, and other kinases,
7BIO causes cell death without affecting any kinase that
has so far been investigated in this context [16]. Employing
these compounds, we are able to test the principle of
inverse screening, and to assess whether it allows the
identification of ligand specific effects at the same time.4, November 2007 ª2007 Elsevier Ltd All rights reserved 1207
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Inverse In Silico Screening of Kinase InhibitorsFigure 1. Docking Results and In Vitro Kinase Assay
(A) Indirubin 30-oxime (thick, atom colored sticks) redocked into a CDK5 structure in complex with indirubin 30-oxime. The resulting score leads to rank
11 for this structure among the kinases and 36 in the complete set of complexes. Themodel is in perfect agreement with the typical interactionmotif of
two or three hydrogen bonds (shown as dashed blue lines) to the protein backbone (shown in the background of this picture). The conformation of
indirubin 30-oxime as found in the PDB structure is shown as thin cyan sticks and shows nearly perfect agreement with the model.1208 Chemistry & Biology 14, 1207–1214, November 2007 ª2007 Elsevier Ltd All rights reserved
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Indirubin-30-oxime (IOX) and the three derivatives were
screened against our database of 6,000 protein binding
sites. Visual examination of single docking results con-
firmed the known docking poses and essential interac-
tions for these compounds in kinases (Figures 1A and 1B).
The results of the virtual inverse screening for the three
indirubin derivatives with all protein binding sites are
shown in Table S1 (see the Supplemental Data available
with this article online). The extracted data for kinase
structures are summarized in Table 1. Virtual inverse
screening for 5BIO, 6BIO and IOX shows significant en-
richment of their well known targets (CDK2, CDK5, GSK-
3b) in the top 1%: overall there are 62 structures of these
proteins in the database. The corresponding enrichment
factors at 1% lie between 16 (5BIO, IOX) and 20 (6BIO).
For 6BIO and IOX, at least one representative for each of
its known targets is found among the 20 best ranked
structures. CDK5 in 5BIO is a false negative as it does
not appear among the 300 best ranked structures.
We identified kinases that ranked well for all three halo-
geno-indirubins: CSK2A,WEE1, CDC2H, RIFK, KSYK, and
PDK1 (Table 1). Since WEE1 is a cell-cycle-associated ki-
nase [17], functional differentiation from effects on CDK2
or CDK5 is hardly possible. RIFK is riboflavin kinase, which
has no known signal transduction activity. From the re-
maining four, we selected PDK1 for experimental valida-
tion. PDK1 shows the most significant differences in the
rankings especially between 5BIO and 6BIO, and is a ther-
apeutically extremely interesting target [18, 19] for which
inhibitors are still rare. PDK1 is downstream of the PI3 ki-
nase and controls many central signaling pathways by
phosphorylating the Akt kinase and the p70S6 kinase,
thereby regulating cell growth and survival [20]. Conse-
quently, PDK1 knockout animals are not viable [20], and in-
creased PDK1 activity is associated with tumor cells [19].
Recently, a further important role for PDK1 has been iden-
tified: the control of motility both in tumor cells [18, 21] and
in endothelial cells [22–24]. Thus, inhibitors of PDK1 might
attack tumors directly (reduction of tumor cell survival and
proliferation), reduce metastasis (by depressing motility of
tumor cells), and inhibit tumor angiogenesis. Finally, PDK1
plays an important role in regulating T cell development
[25], highlighting both the risks of targeting PDK1 for can-
cer therapies and the possibility of addressing T cell
related diseases through inhibitors of PDK1.Chemistry & Biology 14, 1207–1214Figure 1C depicts the modeled complex of 6BIO in
PDK1, which displays perfect interaction geometries.
The binding pocket of PDK1 can easily accommodate
the additional bromine atom (Figure 1D). In contrast,
only poor interaction geometries are found between
7BIO and PDK1 (Figure 1E), which led to a low ranking
(#184). 5BIO lies between these two cases forming rea-
sonable interactions with PDK1, yet identifying it at a sig-
nificantly poorer rank (#77) than 6BIO (#22).
To validate the prediction that PDK1 is a target for 6BIO,
inhibition of PDK1 was tested in vitro: 5BIO and 7BIO
cause inhibition of PDK1 only at high concentrations
(IC50 > 100 mM) (Figure 1F). IO also showed only low po-
tency in this regard (IC50 > 100 mM) (Figure 1F). In a previ-
ous publication, a certain inhibition of PDK1 by IO has al-
ready been described [6]. However, in direct comparison
with IO in our experimental setting, 6BIO showed a
much higher potency and classical kinetics of inhibition
with an IC50 of about 1.5 mM (Figure 1F). Thus, in vitro test-
ing supports our hypothesis that PDK1 is a target for 6BIO.
Biological activity of the compounds in cellular systems
was assessed by examining their influence on proliferation
of two different cell lines. In MCF-7 cells, 6BIO completely
blocked proliferation at 10 mM (Figure 2B), while the other
compounds afforded only 50% inhibition at this concen-
tration (Figures 2A and 2C). For human endothelial cells
(HMEC-1), IC50 values were at about 10 mM with 5BIO
(Figure 2D), 3 mM with 7BIO (Figure 2F), and less than
1 mM with 6BIO (Figure 2E).
The effects of the compounds on cell proliferation could
also be due to inhibition of other kinases. Therefore, we in-
vestigated endothelial cell migration as an additional func-
tional cell-based assay, as this phenomenon has recently
been shown to largely depend on PDK1 activity [24]. After
defined wounding of an endothelial monolayer, migration
caused complete closure of the scratch in the presence
of 10% fetal calf serum within 16 hr (data not shown). In
the absence of serum, the wound stayed completely
open (Figures 3A and 3E). 5BIO and 7BIO caused only
marginal reduction of serum-induced migration at 10 mM
(Figures 3B, 3D, and 3E), while 6BIO inhibited migration
by about 75% at this concentration (Figures 3C and 3E).
As a final test of in vivo activity, we determined phos-
phorylation of two specific downstream targets of PDK:
Akt at the threonine T308 site [26] and p70S6 kinase at
the threonine T229 residue [27]. Phosphorylation was de-
termined in the absence and presence of 10 or 30 mM5BIO,(B) Indirubin 30-oxime (thick, atom colored sticks) docked into a CDK2 structure. This complex has rank 1 among the kinases and rank 5 in the complete
set. Themodel is in perfect agreement with the typical interactionmotif of two or three hydrogen bonds (shown as dashed blue lines) to the protein back-
bone (shown in the background of this picture). The ligand originally contained in the X-ray structure is shown as thin cyan sticks for comparison.
(C) 6-bromo inidirubin 30-oxime model into PDK1 with bound inhibitor staurosporine. The figure shows the good agreement with the backbone
hydrogen bonding motif.
(D) The solvent accessible surface of the binding pocket of PDPK1 together with the VDW-Sphere depiction of 6-bromo inidirubin 30-oxime indicate
that the binding pocket can easily accommodate the halogen.
(E) 7-bromo inidirubin 30-oxime docked into PDK1 with bound inhibitor LY333531. The binding motif is in principle present; however, the geometry of
the hydrogen bonds to the backbone is not optimal.
(F) Dose-response relationships for the three compounds in the in vitro kinase assay for PDK1. 5BIO and 7BIO show inhibition only at the highest
concentration tested (100 mM), whereas 6BIO shows a classical sigmoidal curve with an IC50 of 1.5 mM.
(G) 2D structures of the indirubin derivatives., November 2007 ª2007 Elsevier Ltd All rights reserved 1209
Table 1. The Top 25 Kinase Structures Targeted by Indirubin Derivatives According to Ligand Docking
5
P Kinase Score Rank
1 CDK2 9.13 5
1 CDK2 8.94 6
1 CDK2 8.92 7
1 KITH 8.85 9
1 CDK2 8.60 14
1 GSK3B 8.60 15
1 CDC2H 8.36 28
1 KITH 8.25 35
1 CDK5 8.22 36
1 CDK2 8.20 37
1 CDK2 8.19 38
1 CDK2 8.15 41
1 CDK2 8.11 46
1 WEE1 8.00 51
1 RIFK 7.94 57
1 FGFR1 7.91 59
1 CDK5 7.89 61
1 RIFK 7.88 62
1 CDK2 7.87 65
1 CSK2A 7.85 69
1 CSK2A 7.79 79
1 CDK2 7.79 80
1 CDK2 7.77 84
1 CDK2 7.73 93
1 PDK1 7.69 95
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pxo_CK7 CDK2 8.88 10 1q41_IXM GSK3B 8.73 4 1nb9_RBF RIFK 8.05 8 1pxp_CK8
v0o_INR CDC2H 8.68 19 2bhe_BRY CDK2 8.62 5 1daw_ANP CSK2A 7.98 12 1pxo_CK7
jvp_LIG CDK2 8.47 24 1jvp_LIG CDK2 8.50 9 1lp4_ANP CSK2A 7.87 13 1p2a_5BN
w0x_OLO CDK2 8.46 25 1unh_IXM CDK5 8.44 10 1jvp_LIG CDK2 7.76 17 1p72_THM
n06_ADP RIFK 8.42 26 1x8b_824 WEE1 8.34 11 1x8b_824 WEE1 7.72 20 2bhe_BRY
e9h_INR CDK2 8.39 29 1pye_PM1 CDK2 8.26 12 1p72_THM KITH 7.60 32 1q41_IXM
pkd_UCN CDK2 8.35 31 1lp4_ANP CSK2A 8.24 13 1q41_IXM GSK3B 7.53 36 1v0o_INR
q41_IXM GSK3B 8.32 32 1r78_FMD CDK2 8.10 17 1w0x_OLO CDK2 7.51 38 1p6x_THM
lp4_ANP CSK2A 8.24 35 1v0o_INR CDC2H 8.04 18 1r0p_KSA MET 7.48 40 1unh_IXM
fin_ATP CDK2 8.22 36 1e9h_INR CDK2 7.98 19 1pjk_ANP CSK21 7.47 41 1w0x_OLO
x8b_824 WEE1 8.16 41 1oky_STU PDK1 7.98 22 1day_GNP CSK2A 7.34 56 1pye_PM1
pxp_CK8 CDK2 8.11 44 1fin_ATP CDK2 7.97 23 1csn_ATP CKI1 7.33 58 1e9h_INR
pye_PM1 CDK2 8.08 50 1nb9_RBF RIFK 7.90 26 1om1_IQA CSK2A 7.33 59 1pkd_UCN
vyw_292 CDK2 8.05 54 1aq1_STU CDK2 7.88 27 1z57_DBQ CLK1 7.32 63 1x8b_824
xbc_STU KSYK 8.00 60 1xbc_STU KSYK 7.87 29 1p2a_5BN CDK2 7.26 73 1n06_ADP
nb9_RBF RIFK 7.92 65 1daw_ANP CSK2A 7.79 36 1p6x_THM KITH 7.16 90 1fgi_SU1
sm2_STU ITK 7.84 68 1y6a_AAZ VGFR2 7.77 40 1pye_PM1 CDK2 7.14 94 1unl_RRC
aq1_STU CDK2 7.74 74 1oiq_HDU CDK2 7.73 43 1pxp_CK8 CDK2 7.13 99 1nb9_RBF
oky_STU PDK1 7.73 77 1di8_DTQ CDK2 7.72 46 1di8_DTQ CDK2 7.12 100 1fin_ATP
u59_STU ZAP70 7.72 78 1o6y_ACP PKNB 7.71 47 1e8z_STU PK3CG 6.97 134 1daw_ANP
oit_HDT CDK2 7.67 83 1urw_I1P CDK2 7.71 48 1oiq_HDU CDK2 6.95 140 1lp4_ANP
pjk_ANP CSK21 7.67 84 1uu7_BI2 PDK1 7.70 50 2bhe_BRY CDK2 6.95 141 1pxn_CK6
daw_ANP CSK2A 7.64 86 1p72_THM KITH 7.68 52 1o6y_ACP PKNB 6.92 150 1vyw_292
h1s_4SP CDK2 7.62 90 2biy_ATP PDK1 7.61 63 1q8t_Y27 KAPCA 6.92 151 1jvp_LIG
y6a_AAZ VGFR2 7.60 92 1day_GNP CSK2A 7.59 66 2src_ANP SRC 6.89 162 1oky_STU
he respective ligands were docked to the structures from the Protein Data Base (sc-PDB). The most frequently used abbreviations in the PDB ID co
sporine), IXM (indirubin-30monoxime), and ANP (phoshoaminophosphonic acid-adenylateester). When several structures were available, all were te
e most favorable docking scores are listed in descending order. Known targets of each compound are shown in bold, structures of PDK1 are in bo
nking in the complete screening from Table S1.
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Inverse In Silico Screening of Kinase Inhibitors6BIO, and 7BIO, respectively, in MCF-7 cells. Since phos-
phorylation of both substrates is significantly inhibited by
6BIO, but not by 5BIOor 7BIO in both cell types (Figure 3G),
we can conclude that 6BIO, in contrast to 5BIO and 7BIO,
indeed inhibits PDK1 in vivo at micromolar concentrations.
We have shown that inverse virtual screening is able to
specifically identify cellular targets for small molecules.
Furthermore, in this case, the approach correctly identi-
fied 6BIO as the compound interacting best with PDK1,
thus having qualitatively predicted differences between
very similar compounds. The combined approach de-
scribed here may serve to accelerate and simplify the
drug discovery and development process, and to study
the biological activity profiles of already known and estab-
lished kinase inhibitors. This is still an important issue, as
has recently been shown for LY294002, a well established
PI3 kinase inhibitor: by a work-intensive proteomics ap-
proach, this compound was found to interact with a vast
number of off-target kinases [28].
Compared to purely experimental approaches for find-
ing targets, inverse screening has the advantage of appli-
cability across protein families and functional relevance.
Chemical proteomics approaches [28] have the disadvan-
tage that they only test for binding, not for functionally
Figure 2. Effects of Indirubin Derivatives on Proliferation
MCF-7 cells (A–C) and HMEC-1 cells (D–F) were observed after 72 hr
growth in the absence or presence of the indicated compounds. Pro-
liferation wasmeasured colorimetrically (OD) by using the crystal violet
assay. Error bars denote standard error of the mean taken from three
measurements with three replicas each.Chemistry & Biology 14, 1207–121relevant interactions. Large scale binding affinity assays
require family specific reference ligands for the competi-
tion assay. Inverse screening is less resource intensive;
however, it has the main drawback of the prediction error,
thus requiring experimental validation of predictions, e.g.,
in the type of vertical approach demonstrated in this work.
As such, it is a valuable complementary approach to cur-
rent experimental techniques for identifying new targets
and can be useful in understanding potential drug side ef-
fects, identifying new applications for existing compounds
[29], and interpreting phenotypes induced by a compound
in chemical biology experiments [30].
SIGNIFICANCE
Typical in vitro screening assays for small molecules
only allow testing against one defined target protein.
Thus, potential side effects (or other more important
targets) may be overlooked. In inverse virtual screen-
ing, a high number of protein structures from a protein
data base are virtually tested for inhibitor binding. As
far as we know, we have for the first time applied
this approach to kinases, which comprise a class of
proteins that are most attractive drug targets. This
process has led to the identification of the kinase
PDK1 as an as-yet-unknown target of the indirubin de-
rivative 6BIO. In addition, we were able to validate our
in vitro prognosis in cellular systems. We conclude
that this approach of inverse in vitro screening could
be a valuable tool for facilitating and accelerating the
drug discovery process.
EXPERIMENTAL PROCEDURES
Virtual Inverse Screening
For the structure based virtual screening, the scPDB database of bind-
ing sites was used. Our version contains 5,834 protein structures, rep-
resenting 1,435 unique proteins, when the source organism is ne-
glected. Kinase structures were identified by extracting from the
protein structure database scPDB [31] all complexes annotated with
an EC number beginning with 2.7.1.). The resulting set of kinase struc-
tures contained 327 complexes, representing 84 unique proteins,
when the source organism is neglected. All three compounds used
in this study were docked into each protein structure with the docking
tool GlamDock [32]. The active site for each docking was defined as
a sphere of radius 9A centered on the bound ligand as contained in
the scPDB. Docking was performed under the assumption of a rigid
binding site; however, structural variation in kinase structure is partially
accommodated for by the presence of multiple X-ray structures for
several kinases in complex with different ligands.
The ligands were docked with the standard ChillScore function used
for docking in GlamDock [32]. GlamDock is a Monte Carlo with Minimi-
zation [33]-based docking algorithm,which combines a number of pre-
viously suggestedmethods to obtain high accuracy and high efficiency
predictions. The Monte Carlo search uses a probe based approach for
defining the ligand orientation and an internal coordinate (torsions) de-
scription of ligand conformation. At each step, both orientation and
conformation are changed by a small perturbation, and the ligand is
placed into the binding site according to the new coordinates. A sub-
sequent torsion space minimization with the full energy function is per-
formed for 15 steps, to relax the conformation in the field of the protein.
The ensuing conformation is retained or discarded according to the
Metropolis criterion.4, November 2007 ª2007 Elsevier Ltd All rights reserved 1211
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Most Potently Inhibited by 6BIO
In the scratch wound, migration assay with en-
dothelial cells complete wound closure is ob-
served in the presence of 10% serum (data
not shown). In the absence of serum, the gap
remains open (A). 5BIO and 7BIO did only
moderately influencemigration (B and D), while
6BIO elicited 75% inhibition (C). (E) Quantita-
tive evaluation. Error bars denote standard
error of the mean taken from three measure-
ments with three replicas each. (F–H) 6BIO
inhibits phosphorylation of PDK1-specific sites
in p70S6 kinase (T229) and Akt (T308) inMCF-7
cells. In contrast to 5BIO (F) and 7BIO (H), 6BIO
(G) inhibits phosphorylation of PDK1-specific
targets (indicated by boxes). An irrelevant
phosphorylation site at T389 in p70S6 and
overall content of Akt remain unchanged (F–H).A docking simulation consists of five simulated annealing runs of 300
Monte Carlo steps each, where local minima are kept during all simu-
lations, pose clustered and postminimized with 80 steps of torsion
space minimization. A docking simulation takes approximately 1 min
on a standard PC CPU. The best ranking conformation is predicted
as the structure of the complex. The energy function used for the
minimization and for ranking the conformations is ChillScore, which
is a continuous, differentiable empirical potential derived by fitting in-
teraction energies to binding affinities of known complexes. More
details on the algorithm, the energy function, and a wide ranging
validation are given elsewhere [32]. For the ranking of the different pu-
tative complexes a second variant of the scoring function was used,
which neglects interactions with metal ions present in the kinase active
site.
As indirubin-30-oxime is not known to interact withmetal ions, we as-
sumed that such interactions would also not occur in the binding
modes of the halogenated derivatives. Interactions with metal ions
are, however, strongly favored by standard empirical scoring func-
tions, and ChillScore is no exception to this rule. The reason for this
preference is that empirical scoring functions do not punish metal li-
gand interactions of poor geometry and do not take competition with
water for metal ligand sites correctly into account. The bias toward for-
mation of ligand-metal interactions leads to false hits in the inverse
screening since structures showing such interactions tend to rank
well. To remove this bias from the ranking, the structural models result-
ing from the docking procedure were reranked by a specialized energy
function that ignores ligand-metal ion interactions. This energy func-
tion, a variant of the empirical ChillScore energy function used for1212 Chemistry & Biology 14, 1207–1214, November 2007 ª20docking [32], was derived by performing a two-step least-squares fit
on the complexes and binding affinities reported in the PDBBind data-
base without using the metal-acceptor interaction term. For each
inhibitor, the kinase structures were then sorted in order of increasing
predicted binding free energy (decreasing affinity) for each complex
(Table 1).
In Vitro Kinase Assay
PDK1 protein kinase was expressed in Sf9 insect cells as human re-
combinant GST-fusion protein bymeans of the baculovirus expression
system. The kinase was purified by affinity chromatography with GSH-
agarose. The purity of the kinase was checked by SDS-PAGE/silver
staining, and the identity was verified by mass spectroscopy. A propri-
etary protein kinase assay (33PanQinase assay) was used for measur-
ing the kinase activity of PDK1. All kinase assayswere performed in 96-
well FlashPlates from Perkin Elmer/NEN (Boston, MA, USA) in a 50 ml
reaction volume. The assay for PDK1 contained 60 mM HEPES-
NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3 mM Na-orthovanadate,
1.2 mM DTT, 50 mg/ml PEG20000, 1 mM [g-
33P]-ATP (approx. 5 3 105
cpm per well). The reaction cocktails were incubated at 30C for 80
min. The reaction was stoppedwith 50 ml of 2% (v/v) H3PO4, and plates
were aspirated and washed two times with 200 ml 0.9% (w/v) NaCl. In-
corporation of 33Pi was determined with a microplate scintillation
counter (Microbeta,Wallac). The residual activities for each concentra-
tion and the compound IC50 valueswere calculatedwith QuattroWork-
flow V2.0.2.2 (Quattro Research GmbH,Munich, Germany). Themodel
used was ‘‘Sigmoidal response (variable slope)’’ with parameters
‘‘top’’ fixed at 100% and ‘‘bottom’’ at 0%.07 Elsevier Ltd All rights reserved
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The breast cancer cell line MCF-7 was routinely cultured in RPMI me-
dium supplemented with 10% FCS. Human microvascular endothelial
cells (HMEC-1) were a kind gift by Dr. F.J. Candal from the CDC, At-
lanta, GA, USA. Theses cells were cultured in endothelial growth me-
dium (Provitro, Berlin, FRG) supplemented with 10% serum. Primary
endothelial cells (HUVECs) were isolated from umbilical veins by colla-
genase digestion. Cells were used at passage two or three.
Proliferation Assay
Proliferation of MCF-7 cells or HMEC-1 was examined by using crystal
violet as described in the NCI protocols. Briefly, cells are detached by
trypsinization and seeded at a density of 1,500 per well in 96-well
dishes. After 24 hr, one plate is stained with crystal violet, washed,
and air dried (day 0), the other plates are incubated with the respective
compounds for 72 hr. After this time, the plates are also stained and
dried, the stain is eluted with ethanol and citrate, and absorbance is
measured at 540 nm. Absorption linearly correlates with cell number.
Migration Assay
Confluent HUVEC monolayers were wounded by scratching with a
100 ml pipette tip. Cells were treated with the respective compound
or solvent for 16 hr. The degree of wound closure after this time was
examined microscopically and quantified by using a specially devel-
oped software (S.CO LifeScience, Garching, FRG).
Western Blot Analysis
Lysis of MCF-7 or HMEC-1 cells and gel electrophoresis was per-
formed by standard procedures. The following primary antibodies
were used: rabbit anti-phospho-p70S6 kinase (T229) from R&D sys-
tems, rabbit anti-phospho-p70S6 kinase (T389) from Cell Signaling,
rabbit anti-phospho-Akt (T308) from Cell Signaling, and rabbit
anti-Akt from Cell Signaling. The respective protein was detected by
using fluorescent-labeled secondary antibodies and analysis in an
infrared scanner (Odyssey, LI-COR Biosciences, Bad Homburg,
Germany).
Statistical Analysis
All experiments were performed in triplicates at least in three indepen-
dent sets of experiments. For western blots, one representative blot is
shown. All quantitative data are presented as mean ± standard error
of the mean (SEM). For comparisons with control, one way ANOVA
was used. As a post-hoc test, we used the Student-Newman-Keuls
procedure.
Supplemental Data
Supplemental Data include a table of the screening results over the
complete protein database for the four compounds (5BIO, 6BIO,
7BIO, and IOX) and are available at http://www.chembiol.com/cgi/
content/full/14/11/1207/DC1/.
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